The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

In April 2026, a Nature GWAS of 27,885 GLP-1 medication users found GIPR rs1800437 associated with outcomes specifically in tirzepatide users — not in GLP-1-only agonist users. This article explains what that finding means, why the dual-receptor distinction matters, and why the PlexusDx Precision Peptide Genetic Test directly genotypes this SNP across 34 weight management insights.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including the pathways most relevant to GLP-1 receptor signaling. This article explains what the research shows about genetics and semaglutide response, why MTHFR methylation status matters in the broader metabolic picture, and how genetic testing can help inform a smarter weight management approach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including GLP-1 receptor signaling and GIPR response pathways. This article explains how genes like FTO, MC4R, and PPARG influence appetite, fat metabolism, and weight regulation, and why your DNA may be the most underused variable in any weight management decision.

A Diabetes Care analysis estimates tirzepatide may reduce MACE risk by up to 28% and all-cause mortality by 39% compared to theoretical placebo — a figure the SURPASS-CVOT trial design couldn't directly show. Here's what the imputed placebo data reveals, and why GLP-1 receptor pathway genetics matter before any weight management decision.